Which term covers funding for small pharmaceutical companies developing orphan drugs?

• A. Federal Financial Grants
• B. Phase III Trials
• C. Unlabeled Indications
• D. Medication Package Inserts

Answer: (A)

Funding for small pharmaceutical companies developing orphan drugs often comes from government sources, because rare-disease programs don’t always attract enough private investment. Federal financial grants provide these funds to support research and early development, helping cover costs of discovery, preclinical work, and initial clinical studies. This type of funding is aimed at advancing therapies with public health importance but limited market potential, which is exactly the situation with orphan drugs.

The other options describe actions or documents rather than funding: a phase III trial is a late-stage clinical study, unlabeled indications refer to uses not yet approved, and medication package inserts are the official drug labeling.